Cutera Inc (CUTR) - Product Pipeline Analysis, 2018 Update
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Cutera Inc Company Overview 4
Cutera Inc Company Snapshot 4
Cutera Inc Pipeline Products and Ongoing Clinical Trials Overview 4
Cutera Inc – Pipeline Analysis Overview 6
Cutera Inc - Key Facts 6
Cutera Inc - Major Products and Services 7
Cutera Inc Pipeline Products by Development Stage 8
Cutera Inc Ongoing Clinical Trials by Trial Status 10
Cutera Inc Pipeline Products Overview 12
enlighten 670 nm Laser - Tattoo Removal 12
enlighten 670 nm Laser - Tattoo Removal Product Overview 12
enlighten 670 nm Laser - Tattoo Removal Clinical Trial 13
Enlighten III Laser System - Acne Scars 14
Enlighten III Laser System - Acne Scars Product Overview 14
enlighten Multi-Wavelength - Tattoo Removal 15
enlighten Multi-Wavelength - Tattoo Removal Product Overview 15
enlighten Multi-Wavelength - Tattoo Removal Clinical Trial 16
Next-gen TruSculpt 17
Next-gen TruSculpt Product Overview 17
Cutera Inc - Key Competitors 18
Cutera Inc - Key Employees 19
Cutera Inc - Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Cutera Inc, Recent Developments 21
Jul 16, 2018: Cutera Launches truSculpt iD, Personalized Body Sculpting: The Next Evolution 21
Jul 16, 2018: Cutera Launches truSculpt iD, Personalized Body Sculpting: The Next Evolution 21
Jun 13, 2018: Cutera Announces Expansion of FDA Indications for the truSculpt Body Contouring System 22
May 31, 2018: Cutera Announces Opening of New Office and Training Center in Madrid to the Newly Established Direct Operations in Spain 22
May 08, 2018: Cutera Reports First Quarter 2018 Financial Results 23
Apr 09, 2018: Patent Infringement Suits Filed Today Against 18 Manufacturers and Distributors of Fractional RF Microneedle Systems 24
Feb 15, 2018: Cutera Showcases Expanded Portfolio at AAD 24
Feb 14, 2018: Cutera Reports Fourth Quarter 2017 Financial Results 25
Dec 04, 2017: Cutera Announces Appointment of Sandra Gardiner as CFO 26
Nov 07, 2017: Cutera Reports Third Quarter 2017 Financial Results 26
Appendix 28
Methodology 28
About GlobalData 31
Contact Us 31
Disclaimer 31
Summary
Cutera Inc (Cutera) is a medical device company that manufactures, designs, markets, and services medical and aesthetic devices. The company provides laser and energy based aesthetics systems such as pico technology, excel HR technology, excel V technology, Juliet technology, secret RF technology, truSculpt iD technology, truSculpt 3D technology, and xeo technology. Its products are used in treatment of face and body hair removal and skin revitalization. Cutera’s enlighten device is used for tattoo removals and the treatment of benign pigmented lesions. The company offers truSculpt that delivers deep and uniform heating to all body areas with comfort and ease. It has its operations in France, Australia, Belgium, Italy, Hong Kong, Germany, Canada, Spain, the UK, Portugal, New Zealand, Japan, Switzerland, and the US. Cutera is headquartered in Brisbane, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Cutera Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company